Rocket Pharmaceuticals, Inc.
DE ˙ DB ˙ US77313F1066
2,44 € 0,00 (0,00%)
2026-06-04
DEL PRIS
SecurityDE:9IP1 / Rocket Pharmaceuticals, Inc.
InstitutionBnp Paribas Arbitrage, Sa
Latest Disclosed Ownership269,206 shares
Latest Disclosed Value $ 963,757
Bnp Paribas Arbitrage, Sa ownership in 9IP1 / Rocket Pharmaceuticals, Inc.

On May 12, 2026 - Bnp Paribas Arbitrage, Sa filed a 13F-HR form disclosing ownership of 269,206 shares of Rocket Pharmaceuticals, Inc. (DE:9IP1) valued at $757,815 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 115,165 shares of Rocket Pharmaceuticals, Inc.. This represents a change in shares of 133.76% during the quarter. The current value of the position is $656,863 USD.

Bnp Paribas Arbitrage, Sa has a history of taking positions in derivatives of the underlying security (9IP1) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:9IP1 / Rocket Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F Rocket Pharmaceuticals Equity 77313F106 269,206 154,041 133.76 964 138.37 0.0000
2026-02-10 2025-12-31 13F Rocket Pharmaceuticals Equity 77313F106 115,165 -262,419 -69.50 404 -67.15 0.0002
2025-11-13 2025-09-30 13F Rocket Pharmaceuticals Equity 77313F106 377,584 -77,056 -16.95 1,231 10.51 0.0007
2025-08-14 2025-06-30 13F Rocket Pharmaceuticals Equity 77313F106 454,640 320,746 239.55 1,114 24.64 0.0006
2025-05-14 2025-03-31 13F Rocket Pharmaceuticals Equity 77313F106 133,894 -24,545 -15.49 893 -55.15 0.0005
2025-02-14 2024-12-31 13F Rocket Pharmaceuticals Equity 77313F106 158,439 119,482 306.70 1,992 176.91 0.0011
2024-11-13 2024-09-30 13F Rocket Pharmaceuticals Equity 77313F106 38,957 27,914 252.78 720 203.38 0.0005
2024-08-13 2024-06-30 13F Rocket Pharmaceuticals Equity 77313F106 11,043 -31,495 -74.04 238 -79.30 0.0002
2024-05-01 2024-03-31 13F Rocket Pharmaceuticals Equity 77313F106 42,538 -44,049 -50.87 1,146 -55.88 0.0010
2024-02-14 2023-12-31 13F/A-2 Rocket Pharmaceuticals Equity 77313F106 86,587 25,081 40.78 2,595 105.95 0.0029
2024-02-07 2023-12-31 13F/A-1 Rocket Pharmaceuticals Equity 77313F106 86,587 25,081 2,595 0.0004
2024-02-07 2023-12-31 13F Rocket Pharmaceuticals Equity 77313F106 86,587 2,595
2023-11-14 2023-09-30 13F Rocket Pharmaceuticals Equity 77313F106 61,506 11,072 21.95 1,260 25.75 0.0016
2023-08-09 2023-06-30 13F Rocket Pharmaceuticals Equity 77313F106 50,434 -68,689 -57.66 1,002 -50.88 0.0013
2023-05-12 2023-03-31 13F ROCKET PHARMACEUTICALS EQUITY 77313F106 119,123 61,779 107.73 2,041 81.82 0.0029
2023-02-14 2022-12-31 13F Rocket Pharmaceuticals Equity 77313F106 57,344 -127,445 -68.97 1,122 -61.95 0.0017
2022-11-16 2022-09-30 13F/A-1 Rocket Pharmaceuticals Equity 77313F106 184,789 167,412 963.41 2,949 1,133.89 0.0047
2022-11-15 2022-09-30 13F Rocket Pharmaceuticals Equity 77313F106 184,789 167,412 2,949 0.0007
2022-08-12 2022-06-30 13F Rocket Pharmaceuticals Equity 77313F106 17,377 -44,808 -72.06 239 -75.76 0.0004
2022-05-18 2022-03-31 13F/A-1 Rocket Pharmaceuticals Equity 77313F106 62,185 15,392 32.89 986 -3.43 0.0013
2022-02-09 2021-12-31 13F ROCKET PHARMACEUTICALS EQUITY 77313F106 46,793 37,220 388.80 1,021 256.99 0.0015
2021-11-16 2021-09-30 13F/A-1 ROCKET PHARMACEUTICALS EQUITY 77313F106 9,573 -111,471 -92.09 286 -94.67 0.0004
2021-11-12 2021-09-30 13F INOTEK PHARMACEUTICALS EQUITY 77313F106 8,541 -112,503 195 0.0000
2021-08-10 2021-06-30 13F ROCKET PHARMACEUTICALS EQUITY 77313F106 121,044 111,911 1,225.35 5,361 1,223.70 0.0071
2021-05-07 2021-03-31 13F ROCKET PHARMACEUTICALS EQUITY 77313F106 9,133 3,817 71.80 405 39.18 0.0006
2021-02-10 2020-12-31 13F INOTEK PHARMACEUTICALS EQUITY 77313F106 5,316 -3,225 -37.76 292 49.23 0.0005
2020-10-30 2020-09-30 13F INOTEK PHARMACEUTICALS EQUITY 77313F106 8,541 5,107 148.72 195 174.65 0.0003
2020-08-06 2020-06-30 13F INOTEK PHARMACEUTICALS EQUITY 77313F106 3,434 -8,951 -72.27 72 -58.72 0.0001
2020-05-13 2020-03-31 13F INOTEK PHARMACEUTICALS EQUITY 77313F106 12,385 8,930 258.47 173 120.51 0.0004
2020-02-12 2019-12-31 13F INOTEK PHARMACEUTICALS EQUITY 77313F106 3,455 -640 -15.63 79 65.96 0.0001
2019-11-07 2019-09-30 13F INOTEK PHARMACEUTICALS EQUITY 77313F106 4,095 1,447 54.65 48 20.51 0.0001
2019-07-30 2019-06-30 13F INOTEK PHARMACEUTICALS EQUITY 77313F106 2,648 -2,292 -46.40 40 -54.65 0.0001
2019-04-25 2019-03-31 13F INOTEK PHARMACEUTICALS EQUITY 77313F106 4,940 4,940 87 0.0002
2019-02-12 2018-12-31 13F INOTEK PHARMACEUTICALS EQUITY 77313F106 0 -682 -100.00 0 -100.00
2018-11-07 2018-09-30 13F INOTEK PHARMACEUTICALS EQUITY 77313F106 682 -86 -11.20 17 6.67 0.0000
2018-07-25 2018-06-30 13F INOTEK PHARMACEUTICALS EQUITY 77313F106 768 767 76,700.00 15 79,247.37 0.0000
2018-05-11 2018-03-31 13F INOTEK PHARMACEUTICALS EQUITY 77313F106 1 1 0 0.0000
2018-03-05 2017-12-31 13F/A-1 INOTEK PHARMACEUTICALS STOCK 45780V102 0 -4 -100.00 0 -100.00 0.0000
2017-11-03 2017-09-30 13F INOTEK PHARMACEUTICALS STOCK 45780V102 4 0 0.00 0 -12.50 0.0000
2017-08-03 2017-06-30 13F INOTEK PHARMACEUTICALS STOCK 45780V102 4 -98 -96.08 0 -96.08 0.0000
2017-05-03 2017-03-31 13F INOTEK PHARMACEUTICALS STOCK 45780V102 102 -881 -89.62 0 -100.00 0.0000
2017-02-14 2016-12-31 13F INOTEK PHARMACEUTICALS STOCK 45780V102 983 -204 -17.19 6 -54.55 0.0000
2016-10-05 2016-09-30 13F * INOTEK PHARMACEUTICALS CORP COM STOCK 45780V102 1,187 497 72.03 11 120.00 0.0000
2016-07-06 2016-06-30 13F * INOTEK PHARMACEUTICALS CORP COM STOCK 45780V102 690 690 5 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2025-02-14 2024-12-31 13F Rocket Pharmaceuticals Option Call 0 -100.00 0 -100.00 n/a n/a n/a
2024-11-13 2024-09-30 13F Rocket Pharmaceuticals Option Call 367 678 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.